文献速递其他结缔组织病

大麻素2型受体激动剂来那巴姆在弥漫性皮肤型系统性硬化症3期随机试验中的疗效与安全性

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2023-06-15

这项3期多国双盲研究纳入365例弥漫性皮肤型系统性硬化症患者,按1:1:1随机接受来那巴姆20 mg、5 mg或安慰剂每日两次,均叠加于背景治疗。第52周时来那巴姆20 mg组与安慰剂组的美国风湿病学会dcSSc综合应答指数(CRISS)分别为0.888和0.887,未达主要终点。未观察到与来那巴姆相关的死亡或严重/重度不良事件增多。

要点

  • 来那巴姆20 mg每日两次组第52周CRISS为0.888,安慰剂组为0.887,主要终点未达到。
  • 第52周改良Rodnan皮肤厚度评分(MRSS)变化来那巴姆20 mg组为-6.7,安慰剂组为-8.1,差异无统计学意义。
  • 预设分析显示背景霉酚酸酯治疗及免疫抑制治疗≤1年的患者CRISS更高、MRSS改善更大、用力肺活量下降更少。

核心结论

  • 未证明来那巴姆在弥漫性皮肤型系统性硬化症中的获益。
  • 多数患者接受背景免疫抑制治疗,其中霉酚酸酯治疗与更好的结局相关。
  • 这些发现支持免疫抑制治疗用于弥漫性皮肤型系统性硬化症,并凸显在标准治疗免疫抑制基础上叠加研究性治疗时证明疗效的挑战。

研究设计与样本

  • 多国双盲3期研究,纳入365例弥漫性皮肤型系统性硬化症患者。
  • 患者按1:1:1随机接受来那巴姆20 mg、来那巴姆5 mg或安慰剂,均每日两次,并叠加于包括免疫抑制治疗在内的背景治疗。

主要发现

  • 主要终点第52周CRISS(来那巴姆20 mg每日两次 vs 安慰剂)未达到,CRISS评分0.888 vs 0.887(P=0.4972,采用混合模型重复测量[MMRM])。
  • 第52周MRSS变化(来那巴姆20 mg每日两次 vs 安慰剂)为-6.7 vs -8.1(P=0.1183,采用MMRM)。
  • 预设分析显示,接受背景霉酚酸酯治疗的患者及接受免疫抑制治疗≤1年的患者CRISS评分更高、MRSS改善更大、用力肺活量下降更少。
  • 未观察到与来那巴姆相关的死亡或严重/重度不良事件增多。

临床怎么用

  • 原文结论指出这些发现支持免疫抑制治疗用于弥漫性皮肤型系统性硬化症的治疗。
  • 原文结论指出这些发现对系统性硬化症的试验设计及临床照护具有相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc). METHODS: A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST). RESULTS: The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.888 versus 0.887 (P = 0.4972, using mixed models repeated measures [MMRM]). The change in the modified Rodnan skin thickness score (MRSS) at week 52 for lenabasum 20 mg twice a day versus placebo was -6.7 versus -8.1 (P = 0.1183, using MMRM). Prespecified analyses showed higher CRISS scores, greater improvement in MRSS, and lower decline in forced vital capacity in patients on background mycophenolate and those who were taking IST for ≤1 year. No deaths or excess in serious or severe adverse events related to lenabasum were observed. CONCLUSION: A benefit of lenabasum in dcSSc was not demonstrated. Most patients were treated with background IST, and treatment with mycophenolate mofetil in particular was associated with better outcomes. These findings support the use of IST in the treatment of dcSSc and highlight the challenge of demonstrating a treatment effect when investigational treatment is added to standard of care IST. These findings have relevance to trial design in SSc, as well as to clinical care.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Spiera R, Kuwana M, Khanna D, et al. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023. PMID: 37098795. doi:10.1002/art.42510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。